Literature DB >> 3945037

Carbamazepine-erythromycin interaction. Case studies and clinical significance.

B A Wroblewski, W D Singer, J Whyte.   

Abstract

Because of significant and seemingly haphazard fluctuations in serum carbamazepine concentrations, we decided to investigate the possible link between erythromycin administration and potential changes in serum carbamazepine concentration. We studied four cases involving this combination. In every case, serum carbamazepine concentrations either rose dramatically (doubled or tripled previous steady-state concentrations) or dropped precipitously once erythromycin therapy was discontinued. In all cases, we report serum carbamazepine concentrations obtained before, during, and after concurrent erythromycin administration. We conclude that the combination of erythromycin and carbamazepine represents a clinically significant drug interaction and should be avoided where possible.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3945037     DOI: 10.1001/jama.255.9.1165

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

Review 1.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

2.  Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels.

Authors:  D C Metz; H D Getz
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

Review 3.  Principles of antibiotic prescribing in the elderly.

Authors:  F Borrego; R Gleckman
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 4.  Assessment and treatment of bipolar disorder in the elderly.

Authors:  J H Eastham; D V Jeste; R C Young
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

Review 5.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

6.  Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite.

Authors:  N Barzaghi; G Gatti; F Crema; M Monteleone; C Amione; L Leone; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

Review 7.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 8.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.